Neuren Pharmaceuticals Ltd
ASX:NEU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
AU |
|
Curtiss-Wright Corp
NYSE:CW
|
US |
|
B
|
BlackRock Inc
BMV:BLK
|
US |
|
UPL Ltd
NSE:UPL
|
IN |
|
United Therapeutics Corp
NASDAQ:UTHR
|
US |
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
US |
|
I
|
International Container Terminal Services Inc
XPHS:ICT
|
PH |
|
National Beverage Corp
NASDAQ:FIZZ
|
US |
|
Krafton Inc
KRX:259960
|
KR |
Wall St Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for NEU is 23.92 AUD with a low forecast of 18.79 AUD and a high forecast of 30.45 AUD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NEU's stock price target?
Price Target
23.92
AUD
According to Wall Street analysts, the average 1-year price target for NEU is 23.92 AUD with a low forecast of 18.79 AUD and a high forecast of 30.45 AUD.
What is the Revenue forecast for Neuren Pharmaceuticals Ltd?
Projected CAGR
38%
Over the last 14 years, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 3 years is 38%.
What is the Operating Income forecast for Neuren Pharmaceuticals Ltd?
Projected CAGR
132%
The compound annual growth rate for Operating Income over the next 4 years is 132%.
What is the Net Income forecast for Neuren Pharmaceuticals Ltd?
Projected CAGR
119%
The compound annual growth rate for Net Income over the next 4 years is 119%.
